Nektar Presents New Preclinical Data for NKTR358 a FirstinClass Regulatory T Cell Stimulator at 13th World Congress of Inflammation in London

SAN FRANCISCO July 10 2017 PRNewswire Nektar Therapeutics NASDAQ NKTR today announced positive preclinical results for NKTR358 a firstinclass resolution therapeutic for autoimmune disease. The new preclinical data demonstrate that treatment with NKTR358 i...